Innovators and generics, neither are wholly satisfied with the current Canadian system of intellectual property and related rights (IPRs). Ongoing trade negotiations between Canada and the European Union has fuelled the debate over effective IPR for innovative pharmaceutical products.
Click here to read the full article, written by Steven B. Garland and Daphne C. Lainson of our Ottawa office, which appeared in the August 2012 issue of Intellectual Property Magazine.
Related Publications & Articles
-
Confidential rebate reporting and new price regulatory factors of the amended Patented Medicines Regulations declared invalid by the Quebec Court of Appeal
On February 18, 2022, the Court of Appeal of Quebec released its decision in Merck Canada inc c Procureur général du Canada (2022 QCCA 240). This is the appeal of the Quebec Superior Court decision d...Read More -
Federal Court finds formulation patent relating to ACTONEL DR valid but not infringed
The Federal Court issued its public reasons for judgment in a patent infringement action pursuant to subsection 6(1) of the Patented Medicines (Notice of Compliance) Regulations relating to risedronat...Read More -
Slam dunk! New basket of countries for PMPRB reporting remain, controversial amendments to Patented Medicines Regulations dropped
On April 14, 2022, the Minister of Health announced that the Amendments to the Patented Medicines Regulations (the “Regulations”), originally released on August 18, 2019, would come into force on July...Read More